Michael Nelson is the CEO of Intrommune Therapeutics, whereas Dr. Invoice Reisacher sits on its scientific advisory board.
Develop Your Enterprise,
Not Your Inbox
Keep knowledgeable and be a part of our every day publication now!
2 min learn
Within the fourth episode of Unicorn Hunters (a present that provides viewers not solely a deeper look into the type of conversations that happen between highly effective buyers and entrepreneurs, but additionally permits viewers to develop into buyers themselves), the panel examines Intrommune. Represented by two Cornell graduates, Intrommune was began to fight meals allergic reactions. As Senior Scientific Advisor Dr. Invoice Reisacher says, some estimates place the variety of folks with meals allergic reactions round 500 million. Dr. Reisacher shares how an allergic response on the age of seven modified the course of his life and helped encourage Intrommune.
Intrommune gives a toothpaste that delivers meals proteins to the immune system with out having to swallow them. Dr. Reisacher claims that analysis has proven common publicity to such proteins inside the mouth may also help folks develop into much less allergic to these meals. With correct upkeep, the toothpaste can put together the physique the following time an unintentional publicity happens. The corporate’s first toothpaste gives a peanut protein, particularly, however CEO Michael Nelson claims that Intrommune’s second product goals to focus on a number of meals that trigger 90% of meals allergic reactions. The FDA accepted Intrommune’s Investigative New Drug utility, which has in flip led to the enrollment of shoppers in part 1 medical trials.
Former White Home Advisor and Unicorn Hunters Investor Moe Vela admits that this story is private for him, too, given his allergic reactions to gluten, soy and peanuts. However will Resiacher and Nelson be capable of flip that preliminary curiosity into an precise funding?
Watch the total video to seek out out, or go to Unicorn Hunters right here.